Mechanisms Underlying Differential D1 versus D2 Dopamine Receptor Regulation of Inhibition in Prefrontal Cortex

Heather Tranatham-Davidson, Laurence C. Neely, Antonieta Lavin, and Jeremy K. Seamans

Physiology and Neuroscience Department, Medical University of South Carolina, Charleston, South Carolina 29425

Typically, D1 and D2 dopamine (DA) receptors exert opposing actions on intracellular signaling molecules and often have disparate physiological effects; however, the factors determining preferential activation of D1 versus D2 signaling are not clear. Here, in vitro patch-clamp recordings show that DA concentration is a critical determinant of D1 versus D2 signaling in prefrontal cortex (PFC). Low DA concentrations (<500 nM) enhance IPSCs via D1 receptors, protein kinase A, and cAMP. Higher DA concentrations (>1 μM) decrease IPSCs via the following cascade: D2 → Gₛ → platelet-derived growth factor receptor → ↑ phospholipase C → ↑ IP₃ → ↑ Ca²⁺ → ↓ dopamine and cAMP-regulated phosphoprotein-32 → ↑ protein phosphatase 1/2A → ↓ GABA₂. Blockade of any molecule in the D2-linked pathway reveals a D1-mediated increase in IPSCs, suggesting that D1 effects are occluded at higher DA concentrations by this D2-mediated pathway. Thus, DA concentration, by acting through separate signaling cascades, may determine the relative amount of cortical inhibition and thereby differentially regulate the tuning of cortical networks.

Key words: prefrontal cortex; dopamine receptors; PDGFR; inhibition; GABA; DARPP-32

Introduction

The prefrontal cortex (PFC) receives dense dopaminergic projections from the ventral tegmental area (VTA) that are essential for optimal cognitive function. Dopamine (DA) and GABAergic interneurons help tune recurrent excitation in PFC networks that may ultimately underlie working memory (Sawaguchi and Goldman-Rakic, 1991; Rao et al., 2000; Constantinidis et al., 2002). Cortical DA alterations lead to cognitive impairments similar to those associated with schizophrenia (Kahn et al., 1994; Egan and Weinberger, 1997). Furthermore, schizophrenics show cortical GABAergic anomalies such as alterations in parvalbumin-positive fast-spiking interneurons (Lewis et al., 1999; Lewis, 2000; Volk et al., 2000). Despite cortical interneuron diversity, DA acts almost exclusively on this class of interneuron (Le Moine and Gaspar, 1998; Gorelova et al., 2002). D1 stimulation increases the excitability of these cells, which enhances evoked and spontaneous IPSCs recorded in pyramidal cells. In contrast, D2 stimulation reduces IPSCs in pyramidal neurons, with varying effects on interneurons (Seamans et al., 2001; Gorelova et al., 2002) (but see Tseng and O’Donnell, 2004). This bidirectional modulation of inhibition via D1 and D2 receptors profoundly affects PFC networks encoding working memory (Durstewitz et al., 2000).

Given the properties of DA-linked signaling, bidirectional effects are not surprising. D1 stimulation activates adenylyl cyclase (AC) activity, which increases protein kinase A (PKA) activity, whereas D2 activation inhibits AC (Kebabian and Greengard, 1971). D1-mediated increases in PKA cause dopamine and cAMP-regulated phosphoprotein (DARPP)-32 phosphorylation and protein phosphatase-1 (PP-1) inhibition, which modulates ion channel function (Blank et al., 1997). D2 stimulation decreases AC–PKA and increases PP-2B dephosphorylation of DARPP-32 (Nishi et al., 2002). These cascades emphasize an important yet unresolved problem for DA signaling. If DA acts on different receptors exerting opposing actions, then a bolus DA release should have offsetting and potentially null physiological actions. Given the importance of DA in normal and pathological conditions involving the PFC, understanding the conditions required for optimal D1- versus D2-mediated neuromodulation is critical.

Intriguing clues suggest that the functional effects of DA are concentration dependent. Low [DA] (<1 μM) evoked by DA axon stimulation in vivo increased striatal single-unit firing, whereas higher concentrations decreased this activity (Williams and Millar, 1990). In PFC, low [DA] increased NMDA responses yet reduced them at higher concentrations (Zheng et al., 1999). Given the different affinities of DA receptors (Seeman and Van Tol, 1994) and their varying expression levels and neuronal localization in the cortex (Goldman-Rakic, 1990; Vincent et al., 1993; Gaspar et al., 1995), each receptor may encounter different DA levels. Therefore, the amount of DA released may determine the receptor subtype activated and ultimately affect the tuning of PFC networks that encode working memory.

We hypothesized that low [DA] would preferentially activate...
D1 receptors, increasing inhibitory activity in PFC, and high [DA] would decrease inhibition via D2 receptor activation but through separate signaling pathways. We performed whole-cell patch-clamp recordings from pyramidal cells in cortical slices and evoked IPSCs before and after bath application of various DA concentrations. In addition, we applied inhibitors targeting various stages of DA signaling to determine the molecules responsible for the functional modulation of IPSCs.

Materials and Methods

Brain slice preparation and whole-cell patch-clamp recordings. Sprague Dawley rats (Harlan, Indianapolis, IN; 14–28 d old) and C57BL/6j mice (Rockefeller University; 14–120 d old) (Fienberg et al., 1998) were lightly anesthetized with chloral hydrate (15 mg/kg). After decapitation their brains were rapidly dissected and immersed for 1 min in cold (4°C) oxygenated (carbogen, 95% O2–5% CO2) artificial CSF (ACSF) containing (in mM): 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 0.5 CaCl2, 6 MgCl2, 25 n-glucose, 1.3 ascorbic acid, and 125 NaCl. Sucrose (200 mM) was routinely substituted for NaCl to prevent excitotoxic damage resulting from severing axons during slicing. Slices (300 μm) containing the prelimbic–infralimbic region of the PFC, the region flanked by the corpus callosum in coronal sections (Paxinos and Watson, 1982; Uylings and van Eden, 1990), were transferred to ACSF containing (in mM): 126 NaCl, 3 KCl, 26 NaHCO3, 1 MgCl2, 1.3 ascorbic acid, and 10 n-glucose until use. Recording solution contained (in mM): 126 NaCl, 3 KCl, 26 NaHCO3, 1.3 MgCl2, 2.3 CaCl2, 1.3 ascorbic acid, and 10 n-glucose. Submerged slices in the recording chamber were perfused with recording solution at a rate of 1–3 ml/min and viewed using differential interference contrast optics. Recordings were made at 33–36°C. Thick-walled borosilicate pipettes (3–7 MΩ tip resistance) were used for whole-cell patch-clamp recordings and filled with (in mM): 125 potassium glutonate, 3 KCl, 2 MgCl2, 10 HEPES, 0.1–10 EGTA (see Results), 1 QX-314 Cl. Pipettes were connected to the headstage of a Heka EPC9/3 amplifier with an Ag/AgCl wire. The EPC9/3 was connected to a computer running TIDA software (Heka, Lambrecht, Germany). An Ag/AgCl reference pellet was placed in the bath directly, and voltage shifts were corrected using offset. Voltage-clamp recordings were obtained in continuous single-electrode voltage-clamp mode and filtered at 1 kHz. Capacitance and resistance artifacts were compensated automatically by TIDA and tuned manually. Access resistance was monitored throughout, and a 15% change was deemed acceptable. Bipolar stimulating electrodes, constructed from sharpened epoxy-insulated tungsten wires, were positioned within 200 μm of the soma in layer V. Electrical stimuli consisted of a low-intensity square-wave pulse (20–40 μA; 50 μsec) delivered every 30 sec. o(-) or (±)-d-amino-5-phosphonopentanoic acid (50 μM) and 6,7-dinitroquinoxaline-2,3-dione or 6-cyano-7-nitroquinoxaline-2,3-dione (10 μM) were applied constantly throughout the entire experiment to isolate GABA_A IPSCs. No synaptic response was observed at the same stimulation intensity after subsequent application of bicuculline, suggesting that IPSCs were GABA_A receptor mediated (see Fig. 1).

For applications of DA, the drug was always made fresh, and the carboxylate, which saturated the ACSF, was removed 1–2 min before DA was introduced (to reduce DA oxidation). Overhead and microscope lights were extinguished and DA was applied for 2–3 min. In some experiments, SCH23390 ((R)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride) (5 μM), sulpiride (5–10 μM), L745870 (3-[4-(4-chlorophenyl)piperazin-1-yl][methyl]-1H-pyrrolo[2,3-b]pyridine trihydrochloride) (20 μM), AG1433 (2-(3′,4′-dihydroxyphenyl)-6,7-dimethylquinazoline) (5 μM), H-89 (10 μM), Rp-cAMP (Rp-adenosine-3′5′ cyclic monophosphorothiate triethylenamonium salt) (100 μM), KN-62 (1 μM), chelerythrine (25–75 μM), cypermethrin (4–8 μM), cyclopiazonic A (10–100 μM), or 2-APB (42 μM) was bath applied for 10 min before DA was introduced. In other experiments, EGTA (0.1–10 μM) or calcium A (100 μM) was added to the recording pipette solution. In another group of experiments, slices were incubated for at least 2 hr in ACSF containing 1–2 μg/ml pertussis toxin.

We measured the pH of the ACSF solution used here over a period of 5 min to determine whether removal of oxygen from the bath during the period of DA application contributed to our observed results. ACSF was oxygenated for 30 min and then removed, and pH was measured at 1, 2, 3, and 5 min after removal. The number remained constant at 7.2 throughout this period; therefore, we do not believe that changes in pH can account for the results reported here.

Statistics. Student’s tests were performed comparing average amplitude during baseline with average amplitude during the 15–25 min period after DA application. We first normalized the amplitude measurements so that each value reflected a change relative to the baseline condition. Normally, this consisted of 20 values, because the pulses were delivered every 30 sec and our baseline records lasted 10 min. Asterisks in Figures indicate *p < 0.0001 for a change between these two average values.

Results

Concentration-dependent effects of DA

Various concentrations of DA were applied to acute cortical slices, and a dose-dependent effect on inhibitory transmission was observed. Figure 1 shows the change in amplitude of the IPSC for different concentrations of DA. At low concentrations of DA (10–100 μM), the amplitude of the IPSC was increased (Fig. 1A, C). At higher doses of DA (1–20 μM), an initial decrease in the amplitude of the IPSC was observed (Fig. 1B, C). Summary data shown in Figure 1C were taken from data collected for 10 min.
(15–25 min after DA was applied) (Fig. 1A, B, boxes). Both 10 and 100 nM increased IPSCs, whereas 1 and 10 μM decreased IPSCs, but the 100 nM and 20 μM doses produced the most highly significant effects (Fig. 1) (*p < 0.0001; paired t test). Therefore, the 100 nM and 20 μM concentrations will be used as the “low” and “high” doses of DA, respectively, in all subsequent experiments.

The time course for the DA effects also showed dose dependency (Fig. 1A, B). The low [DA]-mediated increase in IPSC amplitude had an immediate onset and persistent duration, lasting as long as 1.5 hr (Fig. 1B). In contrast, the high dose of DA showed a biphasic effect, during which the decrease in IPSC amplitude had an immediate onset and transient duration followed by a persistent increase in amplitude that lasted throughout the remainder of the recording period (Fig. 1B). These data directly replicate the effect of 20 μM DA on IPSCs reported by Seams et al. (2001). These experiments also show that DA acts in both a concentration- and time-dependent manner to regulate inhibitory cortical transmission.

Control recordings were also performed with ACSF alone, and no significant change in the amplitude of the IPSC was observed over the same recording period of 1–1.5 hr (Table 1). Therefore, the temporal effects of DA application do not appear to be an artifact of long recording sessions or repeated electrical stimulation.

The animals used in these experiments were 14–28 d old. Although it is possible that our results could be reflective of a developmental phenomenon that is subject to change with age, we do not believe this to be the case because we were able to reproduce these results using adult mice (Figs. 2A, 3D).

**DA receptor subtype responsible for dose-dependent effects**

Previous studies have shown that D1 receptor stimulation increases inhibitory neurotransmission in the cortex and D2 receptor stimulation depresses it (Seams et al., 2001; Gorelova et al., 2002) (but see Tseng and O’Donnell, 2004). Therefore, we hypothesized that the concentration dependence of the effects of DA on GABA currents was caused by concentration-specific stimulation of D1 versus D2 receptors. To test this hypothesis, high or low [DA] was applied with D1 and D2 antagonists. The low [DA]-mediated increase in GABA currents was attributable to stimulation of D1 and not D2 receptors (Fig. 1D) because coapplication of low [DA] and the D1 antagonist SCH23390 (5–10 μM) prevented the increase in IPSC amplitude, whereas coapplication of the D2 antagonist sulpiride (5–10 μM) did not.

On the other hand, the high [DA]-mediated decrease in GABA currents was attributable to stimulation of D2 and not D1 receptors because coapplication of the D2 antagonist blocked the effect of high [DA] on the IPSC, whereas coapplication of SCH23390 did not (Fig. 1E). In fact, the IPSC was increased in the presence of a D2 antagonist (see below). Note that application of a D2 antagonist alone before either high or low [DA] had no effect on the IPSC. This argues against a significant contribution of D2 autoreceptors that may be activated by endogenous DA and contribute to the modulatory action on IPSCs.

Previous work has implicated D4 activation in the attenuation of IPSCs, whereas 1 and 10 μM decreased IPSCs, but the 100 nM and 20 μM doses produced the most highly significant effects (Fig. 1) (*p < 0.0001; paired t test). Therefore, the 100 nM and 20 μM concentrations will be used as the “low” and “high” doses of DA, respectively, in all subsequent experiments.

The time course for the DA effects also showed dose dependency (Fig. 1A, B). The low [DA]-mediated increase in IPSC amplitude had an immediate onset and persistent duration, lasting as long as 1.5 hr (Fig. 1B). In contrast, the high dose of DA showed a biphasic effect, during which the decrease in IPSC amplitude had an immediate onset and transient duration followed by a persistent increase in amplitude that lasted throughout the remainder of the recording period (Fig. 1B). These data directly replicate the effect of 20 μM DA on IPSCs reported by Seams et al. (2001). These experiments also show that DA acts in both a concentration- and time-dependent manner to regulate inhibitory cortical transmission.

Control recordings were also performed with ACSF alone, and no significant change in the amplitude of the IPSC was observed over the same recording period of 1–1.5 hr (Table 1). Therefore, the temporal effects of DA application do not appear to be an artifact of long recording sessions or repeated electrical stimulation.

The animals used in these experiments were 14–28 d old. Although it is possible that our results could be reflective of a developmental phenomenon that is subject to change with age, we do not believe this to be the case because we were able to reproduce these results using adult mice (Figs. 2A, 3D).

**DA receptor subtype responsible for dose-dependent effects**

Previous studies have shown that D1 receptor stimulation increases inhibitory neurotransmission in the cortex and D2 receptor stimulation depresses it (Seams et al., 2001; Gorelova et al., 2002) (but see Tseng and O’Donnell, 2004). Therefore, we hypothesized that the concentration dependence of the effects of DA on GABA currents was caused by concentration-specific stimulation of D1 versus D2 receptors. To test this hypothesis, high or low [DA] was applied with D1 and D2 antagonists. The low [DA]-mediated increase in GABA currents was attributable to stimulation of D1 and not D2 receptors (Fig. 1D) because coapplication of low [DA] and the D1 antagonist SCH23390 (5–10 μM) prevented the increase in IPSC amplitude, whereas coapplication of the D2 antagonist sulpiride (5–10 μM) did not.

On the other hand, the high [DA]-mediated decrease in GABA currents was attributable to stimulation of D2 and not D1 receptors because coapplication of the D2 antagonist blocked the effect of high [DA] on the IPSC, whereas coapplication of SCH23390 did not (Fig. 1E). In fact, the IPSC was increased in the

### Table 1. Percentage change by group

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Percentage change from control</th>
<th>SEM</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>+4.69</td>
<td>1.71</td>
<td>5</td>
</tr>
<tr>
<td>Low DA (100 nM)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 nM DA</td>
<td>+13.08*</td>
<td>10.55</td>
<td>6</td>
</tr>
<tr>
<td>100 nM DA</td>
<td>+25.22*</td>
<td>1.87</td>
<td>5</td>
</tr>
<tr>
<td>100 nM DA plus SCH23390</td>
<td>+5.52</td>
<td>1.64</td>
<td>4</td>
</tr>
<tr>
<td>100 nM DA plus Rp-cAMP</td>
<td>−6.39</td>
<td>4.25</td>
<td>6</td>
</tr>
<tr>
<td>100 nM DA plus H-89</td>
<td>−6.67</td>
<td>1.23</td>
<td>4</td>
</tr>
<tr>
<td>100 nM DA plus sulpiride</td>
<td>+25.87*</td>
<td>1.30</td>
<td>4</td>
</tr>
<tr>
<td>100 nM DA plus AG 1433</td>
<td>+16.27*</td>
<td>1.00</td>
<td>3</td>
</tr>
<tr>
<td>100 nM DA plus 2-APB</td>
<td>+5.82</td>
<td>1.31</td>
<td>4</td>
</tr>
<tr>
<td>100 nM DA plus EGTA</td>
<td>+44.61*</td>
<td>2.19</td>
<td>3</td>
</tr>
<tr>
<td>100 nM DA plus calyculin A</td>
<td>+23.54*</td>
<td>2.41</td>
<td>4</td>
</tr>
<tr>
<td>100 nM DA plus KN-62</td>
<td>+16.91*</td>
<td>0.63</td>
<td>3</td>
</tr>
<tr>
<td>100 nM DA in DARPP-32 KO</td>
<td>+17.62*</td>
<td>3.94</td>
<td>4</td>
</tr>
<tr>
<td>High DA (500 nM to 20 μM)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>500 nM DA</td>
<td>−6.477</td>
<td>2.85</td>
<td>9</td>
</tr>
<tr>
<td>1 μM DA</td>
<td>−3.76</td>
<td>4.38</td>
<td>4</td>
</tr>
<tr>
<td>10 μM DA</td>
<td>−12.87</td>
<td>3.16</td>
<td>4</td>
</tr>
<tr>
<td>20 μM DA</td>
<td>−33.10*</td>
<td>1.55</td>
<td>7</td>
</tr>
<tr>
<td>20 μM DA plus sulpiride</td>
<td>+33.46*</td>
<td>3.22</td>
<td>4</td>
</tr>
<tr>
<td>20 μM DA plus L745870</td>
<td>−16.12*</td>
<td>1.87</td>
<td>6</td>
</tr>
<tr>
<td>20 μM DA plus pertussis toxin</td>
<td>+5.00</td>
<td>1.18</td>
<td>7</td>
</tr>
<tr>
<td>20 μM DA plus AG 1433</td>
<td>+27.83*</td>
<td>3.58</td>
<td>7</td>
</tr>
<tr>
<td>20 μM DA plus 2-APB</td>
<td>+13.48</td>
<td>2.21</td>
<td>4</td>
</tr>
<tr>
<td>20 μM DA plus EGTA</td>
<td>+10.84*</td>
<td>1.80</td>
<td>2</td>
</tr>
<tr>
<td>20 μM DA plus EGTA (1 μM)</td>
<td>+0.68</td>
<td>1.01</td>
<td>5</td>
</tr>
<tr>
<td>20 μM DA plus calyculin A</td>
<td>−1.02</td>
<td>1.90</td>
<td>4</td>
</tr>
<tr>
<td>20 μM DA plus SCH23390</td>
<td>−39.12*</td>
<td>2.69</td>
<td>3</td>
</tr>
<tr>
<td>20 μM DA plus H-89</td>
<td>−28.63*</td>
<td>0.93</td>
<td>5</td>
</tr>
<tr>
<td>20 μM DA plus chelerythine</td>
<td>−25.87</td>
<td>3.52</td>
<td>3</td>
</tr>
<tr>
<td>20 μM DA plus KN-62</td>
<td>−25.70</td>
<td>4.64</td>
<td>4</td>
</tr>
<tr>
<td>20 μM DA plus pervemethrin</td>
<td>−38.24</td>
<td>1.39</td>
<td>11</td>
</tr>
<tr>
<td>PP-2B inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 μM DA in DARPP-32 KO</td>
<td>+16.12*</td>
<td>1.57</td>
<td>4</td>
</tr>
<tr>
<td>20 μM DA in WT C57BL/6</td>
<td>−20.66*</td>
<td>0.71</td>
<td>5</td>
</tr>
</tbody>
</table>

*p < 0.001.

### Figure 2.

**Low DA effects are caused by stimulation of the D1–cAMP–PKA pathway but not activation of DARPP-32. A. Inhibition of cAMP (Rp-cAMP) or PKA activity (H-89) prevents the low DA-mediated increase in IPSC amplitude. The last two bars show results from WT and DARPP-32 KO animals. Both the WT and KO animals show the low DA-mediated increase in amplitude. B. Intracellular signaling pathway activated by low DA.**
The high [DA] effect

As shown above, the high dose of DA attenuated IPSC amplitude via D2 receptors (Fig. 1E). Unlike the low [DA]/D1-mediated effect, the high [DA] modulation of IPSCs was unaffected by H-89 (Table 1). Application of this drug for 10 min alone also did not affect the amplitude of the response. Together, these results suggest that the reduction of IPSC amplitude by D2 receptors is not caused by downregulation of PKA.

Recent evidence has shown that D2 stimulation can result in transactivation of the PDGFRβ-associated tyrosine kinase (PDGFRβTK) (Kotecha et al., 2002). Moreover, direct activation of the PDGFR has been shown to modulate GABA currents (Valenzuela et al., 1995). Accordingly, the highly specific inhibitor of PDGFRβTK (AG1433, 5 μM) blocked the effect of high [DA] on IPSCs to almost the same degree as blockade of D2 receptors (Fig. 3A). Although the exact pathway by which D2 receptors accomplish this transactivation is not known, it has been hypothesized to occur through binding of the βγ subunits of the D2-associated G protein to the PDGFR (Oak et al., 2001; Kotecha et al., 2002). The D2 receptor appears to act via this G_βγ-mediated pathway to transactivate the PDGFR and subsequently modulate GABA currents, because high [DA] no longer depressed IPSCs in slices pretreated with pertussis toxin (1–2 μg/ml), which blocks receptor coupling through G_βγ (Fig. 3A).

There are several possible intracellular signaling cascades that could be activated downstream of the PDGFR. PDGFR activation has been shown to modulate both NMDA and GABA currents through increased [Ca^{2+}]_i via IP_3 receptors (Valenzuela et al., 1995; Lei et al., 1999; Kotecha et al., 2002). In our experiments, the high [DA]-mediated reduction in IPSC amplitude was removed by blockade of the IP_3 receptor (2-APB, 42 μM), indicating that intracellular Ca^{2+} was likely involved (Fig. 3A). Therefore, we tested the effects of buffering residual free [Ca^{2+}] on the high [DA]-mediated modulation of IPSC amplitude. Previously, Valenzuela et al. (1995) reported that 500 μM EGTA in the patch pipette essentially abolished the PDGFR-mediated modulation of GABA current in Xenopus oocytes. Moreover, in cortical pyramidal neurons, 100 μM is the maximal EGTA concentration that does not remove synaptic plasticity that is dependent on residual free Ca^{2+} (Rozov et al., 2001). Given these considerations, 100 μM EGTA was typically included in the patch pipettes in the present study to ensure that sufficient [Ca^{2+}]_i was available to mediate any effect. In accordance with Valenzuela et al. (1995), however, additional experiments were performed using higher EGTA concentrations in an attempt to effectively buffer [Ca^{2+}]_i and remove the high [DA]- and PDGFR-mediated modulation of IPSCs in PFC cells. As shown in Figure 3B, the high [DA]-dependent reduction in IPSC amplitude was present only at 100 μM EGTA, whereas at 1 and 10 mM the reduction was not observed. Therefore, as in Xenopus oocytes, the PDGFR-mediated modulation of IPSCs depends strongly on the availability of residual free Ca^{2+}.

The high [DA]-mediated reduction was also blocked by a PP-1/2A antagonist (calyculin A, 10 nM). In addition, the reduction was present in WT mice but absent in recordings from IPSC amplitude in DARPP-32 knock-out (KO) mice, indicating that the effect was DARPP-32 independent. Furthermore, recordings from wild-type (WT) mice showed that the low [DA]-mediated increase in IPSCs was also present in these animals (Fig. 2A). Thus, D1 receptors, cAMP, and PKA, but not DARPP-32, were required for the enhancement in IPSC amplitude observed under low [DA] conditions. (Fig. 2B, pathway summary).

Intracellular pathways mediating the low [DA] effect

Because the low [DA]-mediated increase in IPSC amplitude was attributable to D1 receptor stimulation, we hypothesized that the intracellular pathway involved would be the classic D1–AC–PKA–DARPP-32 pathway (Snyder et al., 1998; Flores-Hernandez et al., 2000). Accordingly, low [DA] appeared to exert its effects via cAMP and PKA activation because coapplication of low [DA] with the PKA inhibitor H-89 (10 μM), or the cAMP inhibitor Rp-cAMP (100 μM), abolished the enhancement in IPSC amplitude (Fig. 2A). In contrast, low [DA] was still effective in increasing of GABA currents in PFC (Wang et al., 2002); however, in the present study coapplication of the D4 antagonist L745870 (20 μM) with high [DA] failed to block the decrease in IPSC amplitude (Table 1).

An examination of the time course of the effects of DA in conjunction with DA antagonists helped to separate the temporal components of this modulation. Application of a D1 antagonist blocks the low [DA]-mediated persistent enhancement of IPSC amplitude so that the amplitude stays constant throughout the recording period (Fig. 1D). Application of a D2 antagonist with high [DA] prevents the early transient decrease in IPSC amplitude (Fig. 1E) associated with the biphasic response. Additionally, application of a D1 antagonist with high [DA] blocked only the second component (enhancement) of the biphasic response, but the transient attenuation of the IPSC remained (Fig. 1E). As shown above, the high dose of DA attenuated IPSC amplitude. Previously, Valenzuela et al. (1995) reported that 500 μM EGTA in the patch pipette essentially abolished the PDGFR-mediated modulation of GABA current in Xenopus oocytes. Moreover, in cortical pyramidal neurons, 100 μM is the maximal EGTA concentration that does not remove synaptic plasticity that is dependent on residual free Ca^{2+} (Rozov et al., 2001). Given these considerations, 100 μM EGTA was typically included in the patch pipettes in the present study to ensure that sufficient [Ca^{2+}]_i was available to mediate any effect. In accordance with Valenzuela et al. (1995), however, additional experiments were performed using higher EGTA concentrations in an attempt to effectively buffer [Ca^{2+}]_i and remove the high [DA]- and PDGFR-mediated modulation of IPSCs in PFC cells. As shown in Figure 3B, the high [DA]-dependent reduction in IPSC amplitude was present only at 100 μM EGTA, whereas at 1 and 10 mM the reduction was not observed. Therefore, as in Xenopus oocytes, the PDGFR-mediated modulation of IPSCs depends strongly on the availability of residual free Ca^{2+}.

The high [DA]-mediated reduction was also blocked by a PP-1/2A antagonist (calyculin A, 10 nM). In addition, the reduction was present in WT mice but absent in recordings from IPSC amplitude in DARPP-32 knock-out (KO) mice, indicating that the effect was DARPP-32 independent. Furthermore, recordings from wild-type (WT) mice showed that the low [DA]-mediated increase in IPSCs was also present in these animals (Fig. 2A). Thus, D1 receptors, cAMP, and PKA, but not DARPP-32, were required for the enhancement in IPSC amplitude observed under low [DA] conditions. (Fig. 2B, pathway summary).

Intracellular pathways mediating the high [DA] effect

As shown above, the high dose of DA attenuated IPSC amplitude via D2 receptors (Fig. 1E). Unlike the low [DA]/D1-mediated effect, the high [DA] modulation of IPSCs was unaffected by H-89 (Table 1). Application of this drug for 10 min alone also did not affect the amplitude of the response. Together, these results suggest that the reduction of IPSC amplitude by D2 receptors is not caused by downregulation of PKA.

Recent evidence has shown that D2 stimulation can result in transactivation of the PDGFRβ-associated tyrosine kinase (PDGFRβTK) (Kotecha et al., 2002). Moreover, direct activation of the PDGFR has been shown to modulate GABA currents (Valenzuela et al., 1995). Accordingly, the highly specific inhibitor of PDGFRβTK (AG1433, 5 μM) blocked the effect of high [DA] on IPSCs to almost the same degree as blockade of D2 receptors (Fig. 3A). Although the exact pathway by which D2 receptors accomplish this transactivation is not known, it has been hypothesized to occur through binding of the βγ subunits of the D2-associated G protein to the PDGFR (Oak et al., 2001; Kotecha et al., 2002). The D2 receptor appears to act via this G_βγ-mediated pathway to transactivate the PDGFR and subsequently modulate GABA currents, because high [DA] no longer depressed IPSCs in slices pretreated with pertussis toxin (1–2 μg/ml), which blocks receptor coupling through G_βγ (Fig. 3A).

There are several possible intracellular signaling cascades that could be activated downstream of the PDGFR. PDGFR activation has been shown to modulate both NMDA and GABA currents through increased [Ca^{2+}]_i via IP_3 receptors (Valenzuela et al., 1995; Lei et al., 1999; Kotecha et al., 2002). In our experiments, the high [DA]-mediated reduction in IPSC amplitude was removed by blockade of the IP_3 receptor (2-APB, 42 μM), indicating that intracellular Ca^{2+} was likely involved (Fig. 3A). Therefore, we tested the effects of buffering residual free [Ca^{2+}] on the high [DA]-mediated modulation of IPSC amplitude. Previously, Valenzuela et al. (1995) reported that 500 μM EGTA in the patch pipette essentially abolished the PDGFR-mediated modulation of GABA current in Xenopus oocytes. Moreover, in cortical pyramidal neurons, 100 μM is the maximal EGTA concentration that does not remove synaptic plasticity that is dependent on residual free Ca^{2+} (Rozov et al., 2001). Given these considerations, 100 μM EGTA was typically included in the patch pipettes in the present study to ensure that sufficient [Ca^{2+}]_i was available to mediate any effect. In accordance with Valenzuela et al. (1995), however, additional experiments were performed using higher EGTA concentrations in an attempt to effectively buffer [Ca^{2+}]_i and remove the high [DA]- and PDGFR-mediated modulation of IPSCs in PFC cells. As shown in Figure 3B, the high [DA]-dependent reduction in IPSC amplitude was present only at 100 μM EGTA, whereas at 1 and 10 mM the reduction was not observed. Therefore, as in Xenopus oocytes, the PDGFR-mediated modulation of IPSCs depends strongly on the availability of residual free Ca^{2+}.

The high [DA]-mediated reduction was also blocked by a PP-1/2A antagonist (calyculin A, 10 nM). In addition, the reduction was present in WT mice but absent in recordings from
DARPP-32 KO mice (Fig. 3D). These data suggest that the pathway illustrated in Figure 3E was responsible for the high [DA]-dependent modulation of IPSCs.

Interestingly, calcineurin A also prevented the D1-mediated prolonged increase observed under conditions of high [DA]. One explanation for this result is that inhibition of PP-2A allows increased phosphorylation of DARPP-32 at a separate site from the one phosphorylated by PKA activation. Phosphorylation at this distinct site would result in inhibition of PKA but an enhancement of PP-1 activity. It is possible that further changes in the activity levels of these two messengers prevent the D1-mediated increase in GABA currents and a more specific inhibitor would produce more consistent results (Nishi et al., 2000).

Increases in \([\text{Ca}^{2+}]_i\), can activate other intracellular signaling molecules that could theoretically be involved in the modulation of IPSCs, including PKC, CaMKII, and calcineurin. As shown in Figure 3C, blockers of each of these molecules did not remove the high [DA]-mediated depression of the IPSC.

It is of interest to note that blockade of PDGFR, \([\text{Ca}^{2+}]_i\), IP3 receptors, PP-1/2A activity, or DARPP-32 KO not only removed the decrease in IPSCs but actually caused high [DA] to increase IPSC amplitude (Fig. 3A), similar to the effect produced by high [DA] in the presence of a D2 antagonist (Fig. 1D). Given that a putative D1 receptor-mediated effect is revealed after application of high [DA] when D2 receptors or its downstream targets were blocked, these data suggest that each component in the hypothalamic D2-linked pathway was not targeted by D1 receptors. Rather, blockade of any component in the D2 receptor-linked pathway prevented the D2-mediated inhibition of postsynaptic GABA responses, yet DA was still free to act on the independent D1-linked pathway to increase IPSC amplitude.

**Discussion**

Our experiments show that DA exerts concentration-dependent effects on cortical inhibition. Lower concentrations preferentially activate D1 receptors, whereas higher concentrations activate both D1 and D2 receptors. In addition, separate signaling pathways mediate D1 versus D2 effects on IPSCs.

**Low [DA] acts via D1 receptors and PKA to increase GABA release**

Our findings show that low [DA] increases IPSCs in pyramidal cells via activation of the D1 receptors cAMP and PKA; however, whether this effect occurs presynaptically or postsynaptically remains unknown. On the one hand, low [DA] or D1 receptor activation increases fast-spiking (FS) interneuron excitability (Gorelova et al., 2002; Trantham-Davidson et al., 2004), causing increases in spontaneous IPSC frequency and evoked IPSC amplitude, indicating presynaptic modulation (Seamans et al., 2001). On the other hand, depending on the composition of cortical GABA$_\alpha$ receptors, this effect could also happen postsynaptically. The PFC expresses receptors containing either $\beta_1$ or $\beta_3$ subunits, which are targets of kinase activity (Moss et al., 1992; Wisden et al., 1992, 1994; Dunn et al., 1996; Li and DeBlas, 1997; McDonald and Moss, 1997); however, these subunits differ because $\beta_1$ subunits contain only one phosphorylation site for PKA (S408) but $\beta_3$ subunits contain two (S408/409). $\beta_3$ phosphorylation at S408 and S409 increases GABA currents, whereas phosphorylation of S409 alone decreases GABA currents (McDonald et al., 1998). Therefore, if the cortical IPSC depends on $\beta_3$-containing receptors, then their additional PKA site would allow bidirectional modulation of this response. Resolution of these issues awaits future investigation.

Surprisingly, we found that D1 stimulation enhances IPSCs independently of DARPP-32 phosphorylation, because we also observed this effect in recordings from DARPP-32 KO mice. As expected, however, cAMP and PKA activation were required. Recent evidence shows that stimulation of D1 receptors (plus cAMP and PKA) increases the excitability of dissociated PFC neurons via suppression of $K^+$ channels similar to the type that are modulated by D1 receptors in intact FS interneurons (Gorelova et al., 2002; Dong and White, 2003; Dong et al., 2004). Therefore, we suggest that if D1-mediated enhancement of IPSCs happens presynaptically, a likely explanation involves DARPP-32-independent $K^+$ channel phosphorylation in FS interneurons.

**High [DA] acts via D2 receptors through a complex signaling pathway to reduce GABA$_\alpha$ IPSCs**

In contrast to the prolonged actions of low [DA]/D1-mediated increases in IPSCs, the high [DA]/D2-mediated IPSC attenuation is more transient. As argued previously, high [DA] may activate D1 and D2 receptors, but the initial D2-mediated reduction in IPSC amplitude occludes the more prolonged D1-mediated enhancement (Seamans et al., 2001). Accordingly, high [DA] delivered after blockade of D2 receptors or related signaling molecules enhanced IPSC amplitude, an effect prevented by D1 antagonism (Fig. 1E).

High [DA] decreased cortical IPSCs possibly via postsynaptic mechanisms. Reports conflict regarding D2 effects on interneurons (Gorelova et al., 2002; Tseng and O’Donnell, 2004) and GABA release measured with $[^{3}H]$GABA release assays and microdialysis in PFC (for review, see Seamans and Yang, 2004). Previous work supporting the idea that this effect occurs postsynaptically showed that D2 stimulation reduced postsynaptic GABA$_\alpha$ responses evoked by focal application of muscimol (Seamans et al., 2001). In addition, [EGTA], or calcineurin A included in the recording pipette, which affects signaling only within the recorded pyramidal neuron, prevents the high [DA] effect.

A highly selective inhibitor of the PDGFR$\beta$ tyrosine kinase (at appropriately low concentrations) blocked the high [DA] effect. Previous work shows that PDGFR activation affects GABA currents in other cell types (Valenzuela et al., 1995) independently of PKC, CaMKII, and calcineurin, although the exact nature of the interaction was not discovered. The present results showed that pertussis toxin blocked the effect of high [DA], indicating Gi involvement. The $\beta_3$ subunit associated with the D2-coupled Gi protein may bind to a phosphorylation site on the PDGFR causing activation of its associated tyrosine kinase activity, PDGFR$\beta$ (Oak et al., 2001; Kotecha et al., 2002). Valenzuela et al. (1995) also showed that activation of the PDGFR caused $[\text{Ca}^{2+}]_i$, elevations via PLC and IP$_3$, an effect that we also observed. Because increased $[\text{Ca}^{2+}]_i$, inactivates DARPP-32 (Nishi et al., 1997), we hypothesized that this would increase PP-1/2A phosphatase activity. Experiments using blocking agents suggested that the signaling pathway responsible for the high [DA]/D2-mediated decrease in IPSCs was as follows: high [DA] $\rightarrow$ D$_2$ $\rightarrow$ G$_i$-PDGFR $\rightarrow$ IP$_3$ $\rightarrow$ $[\text{Ca}^{2+}]_i$ $\rightarrow$ DARPP32 $\rightarrow$ PP-1/2A $\rightarrow$ GABA$_\alpha$.

**Functional implications**

The data shown in Figure 1 replicate previous findings of bidirectional modulation of inhibition by DA (Seamans et al., 2001). Realistic computational models of large-scale PFC networks show that this bidirectional modulation might significantly influence PFC dynamics thought to underlie the active retention of information in working memory (Durstewitz et al., 2000). Specifically, the combination of D1-mediated enhancement of IPSCs...
with D1-mediated increases in Na\(^+\) and NMDA currents causes enhancement of persistent activity states relative to changes in spontaneous activity (Durstewitz et al., 2000; Durstewitz and Seamans, 2002), as observed in vivo (Sawaguchi et al., 1990a,b). D1-mediated alterations in these currents decrease the likelihood that interfering stimuli will interrupt persistent activity. In this way D1 activation enhances the robustness of working memory representations (Durstewitz et al., 2000). We have termed this D1-dominated network dynamic “state 2” (Seamans et al., 2001; Seamans and Yang, 2004).

In contrast, the influence of DA via D2 receptors moves the system away from robustness. This could happen with very strong D1 activation that reduces NMDA currents (Williams and Goldman-Rakic, 1995; Goldman-Rakic et al., 2000; Seamans and Yang, 2004) or strong D2 receptor activation that reduces GABA\(_A\) currents (Fig. 1), NMDA currents (Zheng et al., 1999), and pyramidal cell excitability (Gulledge and Jaffe, 1998, 2001). When D2 activation reduces GABAergic tone, our models show that high persistent activity states tend to “pop out” spontaneously (Durstewitz et al., 2000) and are easily disrupted. Under this condition, networks exhibit less stimulus-dependent tuning because many items are represented nearly simultaneously but none are represented particularly strongly. We have termed this D2-dominated network dynamic “state 1” (Seamans et al., 2001; Seamans and Yang, 2004). State 1 may be important in situations requiring response flexibility, during which many options for action must be held in memory and compared.

The present results build on this theory by showing that these states are established by different DA concentrations (Fig. 4). Accordingly, during a working memory task, cortical DA levels reach nanomolar concentrations (Phillips et al., 2004), and D1 (but not D2) antagonists disrupt performance on such tasks (Seamans et al., 1998). Thus, moderate activation of the mesocortical DA system allows working memory buffers to robustly hold information. The present data also suggest that high micromolar cortical DA levels are required for D2 activation and decreased GABA currents to establish a state 1 dynamic. These levels of extrasynaptic DA in PFC are rarely observed, even with strong burst stimulation (Garris et al., 1993); however, synaptic DA concentrations may be much higher than the concentrations measured extrasynaptically (Phillips and Wightman, 2004). This high intrasynaptic [DA] would not initially activate D1 receptors because they are mainly found extrasynaptically (Smiley et al., 1994; Yung et al., 1995; Caille et al., 1996). Thus, synapticly located D2 receptors may respond first to the high phasic DA levels evoked by a particularly novel or stressful stimulus. This would create a transient state 1 dynamic before DA diffuses into the extrasynaptic space, activating D1 receptors and reestablishing a state 2 dynamic (Seamans and Yang, 2004). Therefore, initial D2-mediated attenuation of IPSCs may only be transient and function to reset networks so that the robustness-enhancing effects of D1 receptor activation are reversed momentarily, allowing new information easy access to working memory buffers and the establishment of new goal-state representations.

This theory does not imply that D1 versus D2 receptors themselves activate PFC networks. Rather, the activity in PFC networks is differentially distributed depending on DA levels. State 1 would favor weak activation of a widespread cortical area, whereas state 2 would favor heightened activation of a small and focused cortical region (Durstewitz et al., 2000; Seamans et al., 2001; Seamans and Yang, 2004). In this scheme, DA does not provide PFC networks with specific information but rather sets them into one of two processing states. In either state, working memory buffers remain able to retain and use information transiently. Glutamatergic and GABAergic systems appear to be critical for the actual generation of persistent activity patterns (Seamans et al., 2003). DA only biases the expression of this activity, making glutamate- and GABA-mediated persistent activity more robust (state 2) or weaker yet more receptive to subsequent inputs (state 1). In this way DA is a true neuromodulator, acting on glutamate and GABA systems, biasing the way they process and maintain information in working memory, although providing no information itself to be held in working memory.

The two-state model of DA modulation in PFC also has implications for treating cognitive deficits of schizophrenia (Seamans and Yang, 2004). We showed that DA acts via different signaling pathways to differentially regulate inhibition, which could regulate PFC networks. Thus, although the DA system has been studied extensively with the goal of developing new antipsychotic medications, perhaps investigation of one of the intracellular molecules targeted selectively by D1 versus D2 receptors will provide novel pharmacotherapeutic strategies.

References
Constantinidou C, Williams GV, Goldman-Rakic PS (2002) A role for inhib-


Kahn RS, Harvey PD, Davidson M, Keefe RS, Apter S, Neale JM, Mohs RC, Gulledge AT, Jaffe DB (2001) Dopamine D(1) and D(2) receptors in neostriatal neurons differ by their expression of D1 and D2 dopamine receptor subtypes. Brain Res Mol Brain Res 58:231–236.


